Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.96
$160.36
▼
$261.00
$37.03B0.11.25 million shs839,661 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.80
-8.3%
$29.17
$23.82
▼
$43.10
$3.52B0.794.14 million shs3.47 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.69%-1.26%+8.17%+18.40%+50.19%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.90%+1.27%+13.76%+16.63%+39.67%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-8.28%-7.55%+6.48%-19.69%-31.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.96
$160.36
▼
$261.00
$37.03B0.11.25 million shs839,661 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.80
-8.3%
$29.17
$23.82
▼
$43.10
$3.52B0.794.14 million shs3.47 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.69%-1.26%+8.17%+18.40%+50.19%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.90%+1.27%+13.76%+16.63%+39.67%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-8.28%-7.55%+6.48%-19.69%-31.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.411.10% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.00-0.64% Downside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.79
Moderate Buy$93.36248.37% Upside

Current Analyst Ratings Breakdown

Latest LLY, VKTX, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$251.00 ➝ $270.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,425.00 ➝ $1,625.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.76$22.73 per share11.07$128.01 per share1.97
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.66$25.20 per share56.78$42.81 per share33.43
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.3421.2615.792.843.37%9.38%5.69%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8144.6728.221.7131.90%86.76%22.03%2/3/2027 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$5.40N/AN/AN/AN/A-117.35%-88.87%N/A

Latest LLY, VKTX, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.06-$1.55-$0.49-$1.55N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, VKTX, and BIIB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.43
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
74127.52 million120.76 millionOptionable

Recent News About These Companies

Should You Trim Or Add To Your Viking Therapeutics Position?
Viking Therapeutics stock trades at EUR 25.68 on Thursday
Viking Therapeutics stock trades at 26.00 euros Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$251.65 -1.75 (-0.69%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$253.00 +1.35 (+0.54%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,431.12 -12.38 (-0.86%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$1,435.07 +3.96 (+0.28%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.80 -2.42 (-8.28%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$26.80 0.00 (0.00%)
As of 11/16/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.